Johnson & Johnson (JNJ) reported a 5% year-on-year rise in sales for Q1 sales — though, in a bitter-sweet twist, it's dropped its future forecast.
Though Covid-19 vaccines sales have been good for the company (go figure), it's dropping the single-dose "one and done" vaccines from its future outlook. Their hopes were for this shot to bring in over $3b in sales… bummer.
But as with all good things in life, balance is key. Whilst sales are up, money is dripping from the money here and there. Case in point: it's recently agreed to settle opioid-related claims with West Virginia for $99m.
Why it matters
You'd think, though, with the US dropping mask mandates from plans and other forms of public transport that people would want to boost their immunity... guess the demand for vaccines are cooling in the US.
